Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis

Abstract Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) results in accelerated bone loss and increased risk of bone fracture. The aim of the present study was to evaluate serum bone markers—sclerostin, Dickkopf-1 (DKK-1) and osteoprotegerin (OPG), in a cohort of 88 PCa patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alice Wang, Nishi Karunasinghe, Lindsay D. Plank, Shuotun Zhu, Sue Osborne, Charis Brown, Karen Bishop, Tiffany Schwass, Sofian Tijono, Michael Holmes, Jonathan Masters, Roger Huang, Christine Keven, Lynnette R. Ferguson, Ross Lawrenson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d34afd32928b417ab49bef681506016d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d34afd32928b417ab49bef681506016d
record_format	dspace
spelling	oai:doaj.org-article:d34afd32928b417ab49bef681506016d2021-12-02T17:57:15ZEffect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis10.1038/s41598-021-94090-y2045-2322https://doaj.org/article/d34afd32928b417ab49bef681506016d2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94090-yhttps://doaj.org/toc/2045-2322Abstract Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) results in accelerated bone loss and increased risk of bone fracture. The aim of the present study was to evaluate serum bone markers—sclerostin, Dickkopf-1 (DKK-1) and osteoprotegerin (OPG), in a cohort of 88 PCa patients without known bone metastases, managed with and without ADT, and to analyse their relationship with bone mineral density (BMD) and sex steroids. The cross-sectional analysis between acute-, chronic- and former-ADT groups and PCa controls showed that sclerostin and OPG levels significantly differed between them (p = 0.029 and p = 0.032). Groups contributing to these significant changes were recorded. There were no significant differences in serum DKK-1 levels across the four groups (p = 0.683). In the longitudinal analysis, significant % decreases within groups were seen for DKK-1 [chronic-ADT (− 10.06%, p = 0.0057), former-ADT (− 12.77%, p = 0.0239), and in PCa controls group (− 16.73, p = 0.0022); and OPG levels in chronic ADT (− 8.28%, p = 0.003) and PCa controls group (− 12.82%, p = 0.017)]. However, % changes in sclerostin, DKK-1, and OPG did not differ significantly over 6-months across the evaluated groups. Sclerostin levels showed significant positive correlations with BMD at baseline in the ADT group, while in PCa controls this correlation existed at both baseline and 6-month time points. Sclerostin correlated negatively with testosterone in former ADT users and in PCa controls. Possible prognostic features denoted by parallel increases in sclerostin and BMD are discussed.Alice WangNishi KarunasingheLindsay D. PlankShuotun ZhuSue OsborneCharis BrownKaren BishopTiffany SchwassSofian TijonoMichael HolmesJonathan MastersRoger HuangChristine KevenLynnette R. FergusonRoss LawrensonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alice Wang Nishi Karunasinghe Lindsay D. Plank Shuotun Zhu Sue Osborne Charis Brown Karen Bishop Tiffany Schwass Sofian Tijono Michael Holmes Jonathan Masters Roger Huang Christine Keven Lynnette R. Ferguson Ross Lawrenson Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
description	Abstract Androgen deprivation therapy (ADT) for men with prostate cancer (PCa) results in accelerated bone loss and increased risk of bone fracture. The aim of the present study was to evaluate serum bone markers—sclerostin, Dickkopf-1 (DKK-1) and osteoprotegerin (OPG), in a cohort of 88 PCa patients without known bone metastases, managed with and without ADT, and to analyse their relationship with bone mineral density (BMD) and sex steroids. The cross-sectional analysis between acute-, chronic- and former-ADT groups and PCa controls showed that sclerostin and OPG levels significantly differed between them (p = 0.029 and p = 0.032). Groups contributing to these significant changes were recorded. There were no significant differences in serum DKK-1 levels across the four groups (p = 0.683). In the longitudinal analysis, significant % decreases within groups were seen for DKK-1 [chronic-ADT (− 10.06%, p = 0.0057), former-ADT (− 12.77%, p = 0.0239), and in PCa controls group (− 16.73, p = 0.0022); and OPG levels in chronic ADT (− 8.28%, p = 0.003) and PCa controls group (− 12.82%, p = 0.017)]. However, % changes in sclerostin, DKK-1, and OPG did not differ significantly over 6-months across the evaluated groups. Sclerostin levels showed significant positive correlations with BMD at baseline in the ADT group, while in PCa controls this correlation existed at both baseline and 6-month time points. Sclerostin correlated negatively with testosterone in former ADT users and in PCa controls. Possible prognostic features denoted by parallel increases in sclerostin and BMD are discussed.
format	article
author	Alice Wang Nishi Karunasinghe Lindsay D. Plank Shuotun Zhu Sue Osborne Charis Brown Karen Bishop Tiffany Schwass Sofian Tijono Michael Holmes Jonathan Masters Roger Huang Christine Keven Lynnette R. Ferguson Ross Lawrenson
author_facet	Alice Wang Nishi Karunasinghe Lindsay D. Plank Shuotun Zhu Sue Osborne Charis Brown Karen Bishop Tiffany Schwass Sofian Tijono Michael Holmes Jonathan Masters Roger Huang Christine Keven Lynnette R. Ferguson Ross Lawrenson
author_sort	Alice Wang
title	Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
title_short	Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
title_full	Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
title_fullStr	Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
title_full_unstemmed	Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
title_sort	effect of androgen deprivation therapy on serum levels of sclerostin, dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d34afd32928b417ab49bef681506016d
work_keys_str_mv	AT alicewang effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT nishikarunasinghe effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT lindsaydplank effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT shuotunzhu effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT sueosborne effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT charisbrown effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT karenbishop effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT tiffanyschwass effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT sofiantijono effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT michaelholmes effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT jonathanmasters effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT rogerhuang effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT christinekeven effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT lynnetterferguson effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis AT rosslawrenson effectofandrogendeprivationtherapyonserumlevelsofsclerostindickkopf1andosteoprotegerinacrosssectionalandlongitudinalanalysis
_version_	1718379075056173056

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis

Ejemplares similares